Overview

Biofeedback is an autonomic response observed during the exposure period to CEMBE. After prospectively evaluating 20 healthy individuals or 40 patients with advanced breast cancer or hepatocarcinoma, it was possible to determine subtle hemodynamic changes consistent with the biofeedback effect associated with exposure to a cancer-specific set of modulated frequencies.

Once CEMBE is administered through an intra-oral administration device, the human body absorbs the energy applied at the level of 0.2-1 mW / kg, with a peak absorption in 10 g of tissue between 55 and 132 mW / kg. Initially, the discriminatory study analyzing 9 hemodynamic parameters recorded beat heart beat in 18 individuals demonstrated a hemodynamic pattern specific for hepatocarcinoma and breast cancer, with sensitivity of 94.1% and 95%, respectively, and specificity of 75% and 95%, respectively. These findings were validated in blind analysis in the remaining 56 patients, confirming the high rate of discriminatory success.

A specific pattern of response associated with exposure of a cancer-specific frequency group was also observed in patients diagnosed with neoplasia, since the control group of healthy individuals did not present these response patterns.

This specific signature of response to CEMBE-modulated exposure to cancer-specific frequencies was significantly altered only in patients with hepatocarcinoma after tumor withdrawal (Costa et al, 2015a).

Eligibility

Inclusion Criteria:

• Healthy volunteers
  • Must be considered healthy, with no known relevant comorbidity.
  • Patients must not be carriers of active malignant neoplasm or have a history of malignant neoplasm.
  • Must be over 18 years old.
  • Must have the ability to understand and provide written Informed Consent.

Patients with hepatocellular carcinoma

• Patients must be diagnosed with inoperable HCC.
• Presence of the primary or metastatic tumor at the time of the procedure.
• Patients diagnosed with hepatic cirrhosis must be restricted to Child-Pugh A or B.
• Patients with AFP> 400 ng/ml and characteristic image do not need histopathological confirmation. However, in patients with serology for active B virus, this AFP value must be greater than 4000 ng/ml. The remaining patients must have histological confirmation of HCC.
• Patients may be in observation or in the course of systemic or intra-hepatic treatment.
• Must have the ability to understand and provide written Informed Consent.

Exclusion Criteria:

• Individuals selected for this study will be excluded if they meet the following exclusion criteria:
  • They cannot stop antihypertensive drugs or beta blockers for at least 24 hours.
  • Have a pacemaker or other implantable device.
  • Pregnant or breastfeeding.
  • Under the age of 18.
  • Patients undergoing radiotherapy or up to 2 weeks after its suspension.
  • Inability to understand and provide written Informed Consent.
  • Child Pugh C hepatic cirrhosis.
  • Patient without definite diagnosis.
  • Absence of primary or metastatic tumor at the time of the procedure.

        Potentially eligible participants will be previously guided by the researcher on the
        objectives and risks of the study in question and will be presented and informed about the
        Free, Prior and Informed Consent document.
        Only after all doubts related to the study have been clarified and the Free, Prior and
        Informed Consent document has been signed, will the study participant be invited and
        scheduled to attend the Oncology Center clinic of Hospital Sírio Libanês.
        Patients must be informed that they may not drink alcohol up to 12 hours before the
        procedure, as there may be interference during the procedure.
        They will also be advised not to use antihypertensive drugs like beta-blockers or calcium
        channel inhibitors 24 hours before the procedure, without resulting in a risk to the
        participant's health.
        In this study, following or follow-up of patients is not foreseen.